FDA Approves First Oral Wegovy Weight-Loss Pill

The U.S. Food and Drug Administration has approved a daily oral version of the popular weight-loss drug Wegovy, marking a major milestone in obesity treatment. This first-of-its-kind GLP-1 weight-loss pill from Novo Nordisk contains the same active ingredient, semaglutide, found in the injectable Wegovy and Ozempic, and is expected to expand access to those who prefer a pill over injections.

FDA Grants First-Line Approval for Enhertu Combination in HER2-Positive Breast Cancer

The U.S. Food and Drug Administration has approved AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu (fam-trastuzumab deruxtecan) in combination with Roche’s Perjeta as a first-line treatment for adults with unresectable or metastatic HER2-positive breast cancer confirmed by an FDA-approved test.

This new indication is supported by positive results from the Phase III DESTINY-Breast09 trial, which showed the Enhertu-Perjeta regimen significantly improved median progression-free survival (40.7 vs. 26.9 months) and reduced the risk of disease progression or death compared with the previous standard of care (taxane, trastuzumab and pertuzumab).

The approval expands Enhertu’s use beyond later-line settings, where it had previously earned FDA clearance, and could establish the combination as a new frontline standard of care in this aggressive oncology segment

Click here to read the entire article.

Do not share sensitive information with ChatGPT and other AI chatbots

Experts are warning users not to share sensitive information with ChatGPT and other AI chatbots because the data you type can be stored, analyzed, and used to improve models — and may not remain private. The key categories of information you should avoid sharing include personally identifiable details (name, address, IDs), intimate personal life details, medical and health information, confidential work or proprietary business data, and financial information like bank or credit card details.

UCB Announces Plan to Seek Regulatory Approval for Fintepla in CDKL5 Deficiency Disorder Following Positive Phase 3 Results

UCB announced that it will move forward with regulatory submissions for Fintepla® (fenfluramine) as a treatment for seizures associated with CDKL5 Deficiency Disorder (CDD), following highly positive results from its Phase 3 clinical trial. This represents a potential third indication for Fintepla, which is already approved for Dravet syndrome and Lennox-Gastaut syndrome.

Gen Z Is Rewriting Office Culture

As Gen Z returns to the office in growing numbers, they’re not just filling the physical space — they’re transforming it. According to a CNBC article, this generation is leaning into authenticity, mental health, and digital fluency, bringing new energy to work environments older generations may no longer frequent. From candid check-ins on well-being, to dressing casually and speaking in their own voice, to fully embracing AI tools as collaborators — Gen Z is reshaping corporate norms on its own terms.

Smarter Pharmaceutical Warehousing Starts With Sharper Investments

Warehouse operations in the pharmaceutical sector are no longer background infrastructure. They’re active levers for efficiency, compliance, and product integrity. With regulatory pressures mounting and logistics complexity rising, warehouses have become critical control points, not just for inventory, but for reputation. That means companies can’t afford to treat upgrades as piecemeal patches. They need targeted investment in systems, design, people, and architecture. This article breaks down the most high-impact areas where pharmaceutical companies should be putting real money, not just attention.